Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials

Soquelitinib Monotherapy Yields Durable Responses in Peripheral T-Cell Lymphoma

Final phase 1/1b data for soquelitinib in T-cell lymphoma showed a 37.5% ORR and a 28.1-month median OS in patients who received 1 to 3 prior lines of therapy.